A meta-analysis of biological variation in blood-based therapy as a precursor to bio-manufacturing Currently cellular therapies, such as haematopoietic stem cell transplantation ( HSCT ), are 22
produced at a small scale on case-by-case basis, usually in a clinical or near-clinical setting. 23
Meeting the demand for future cellular therapies will require a robust and scalable 24 manufacturing process that is either designed around, or controls the variation associated with 25 biological starting materials. 26
Understanding variation requires both a measure of the allowable variation ( that does not 27 negatively affect patient outcome ) and the achievable variation ( with current technology ). 28
The prevalence of HSCT makes it an ideal case study to prepare for more complex biological 29 manufacturing with more challenging regulatory classifications. 30
A systematic meta-analysis of the medical literature surrounding HSCT has been completed 31 of which the key outcomes are; 32 data thus providing a demonstration of the current 'state of control'. The research 96 presented here focuses on the results of the literature meta--analysis. 97
Online databases and health resources ( Pubmed and Web of Knowledge ) were used to 98 search the literature for a number of pre--determined keywords, medical search headings 99 ( MeSH ) and publication dates. Articles were restricted to English language, unless a native 100 translation was provided, and only refereed journals were used ( conference proceedings, 101 for example, were excluded ). 102
The abstracts of the resultant studies were then screened for the likelihood of containing 103 applicable data, such as clinical trials or outcomes studies. Eligible publications were then 104 obtained in full and stored locally, and given a unique identifier that could be linked to the 105 database for future reference. These publications were then manually examined for patient, 106 donor and graft measurements. A pre--determined checklist of measurements had been 107 previously created for this task, from mind--mapping and stakeholder discussion ( see Table  108 1 ). A number of primary characteristics, such as the presence of TNC count or CD34+ cell 109 count, were mandatory for studies to pass through to the data collection stage. At this stage, 110 data was transferred and stored next to the identification number within a database. MS 111 Excel and IBM SPSS 22.0 ( New York ) were used for the analysis. Variation was measured from reported cell metrics, of which total nucleated cell count 117 ( TNC ) and CD34+ cell count were most prevalent. These were reported as TNC / kg and 118 CD34+ cells / kg patient bodyweight. Interquartile ranges were often provided in lieu of 119 range data within articles, but were not recorded as they are not representative of the true 120 value of biological disparity and avoid up to 50% of possible variation. Cord blood and 121 paediatric datapoints were removed ( due to low incidence level ) so this dataset represents 122 adult bone marrow and peripheral blood derived material only. It should be noted that in 123 certain figures the x axis title refers to the unique identifying number given to each validstudy, however data in each of these figures is discontinuous and consequently explicit 125 numbering has been omitted. 126
Biological metrics, such as CD34+ cell count, were heavily negatively skewed, probably due 127 to the presence of these cells being host--state dependant or the minimum collection criteria. 128
Non--parametrically distributed data requires a different statistical approach -for example 129
Spearmans Rank Order Correlation ( SROC ) was used for bivariate analysis, rather than the 130 traditional Pearson Product--Moment Correlation used in normally distributed data. The 131 value for SROC refers to the strength and direction of the correlation, the p--value refers to 132 the statistical significance of the test, and the n--value refers to the number of data--points 133 included in the analysis. 134
The results of the meta--analysis are presented as a summary in italics which prefixes the 135 explanation that follows. 136
Overall Variation 137
Under the practise of medicine, the variation currently encountered in HSCT 138 A number of studies have reported a minimum of zero collected or transplanted cell 152 counts which are very particular extremes. It is unlikely this is a true value of sero,but rather that insufficient cells were mobilised and was deemed unviable in the 154 study. These values, as much as they must be considered as a representation of an 155 individuals' personalised medicine, skew the overall analysis of variation 156 considerably. Including the zero values the variation is up to 9 orders of magnitude, 157 whilst excluding them the variation is up to 6 orders of magnitude. For this 158 discussion only quantifiable collected / transplanted cell counts have been used -159 stating the variation can be up to 9 orders of magnitude because of these zero 160 values is clearly misleading. 161
Stratification of the Overall Variation into Collected and Transplanted 162

Allogeneic--derived material can vary up to 6 orders of magnitude of the median cell 163 count, whilst autologous--derived material can vary up to 4 orders of magnitude. 164
Figures 2 and 3 stratify cCD34 / kg / study and tCD34 / kg / study into transplant type 165 and cell source. Only autologous peripherally sourced material was recorded with 166 any magnitude in Figure 2 . The ranges between extremes, and the variation in orders 167 of magnitude of the median value, have been annotated on the diagram accordingly. 168
The variation in cCD34 is up to four orders of magnitude of the median value 169 ( 3.00e5 cells / kg to 2.98e8 cells / kg, n = 86 ). There was insufficient data to stratify 170 between autologous and allogeneic. 171
The variation in tCD34 is; 172
• up to six orders of magnitude of the median value for allogeneic therapy 173 ( 1.00e3 cells / kg to 1.21e9 cells / kg, n = 188 ) 174
• up to four orders of magnitude of the median value for autologous therapy 175 ( 6.00e4 cells / kg to 3.00e8 cells / kg, n = 110 ) 176
As a result, autologous therapy appears considerably more manageable from a 177 variation perspective than allogeneic therapy. Further stratification will be required 178 to determine the reason for the greater amount of variation present within 179 allogeneically sourced material. 180
Variation as a Function of Time 181
Overall, there has been limited improvement ( or apparent drive to improve ) in the 182
community's ability to control variation over a thirty year time period. 183 refers to the observation that 80% of the effect is due to 20% of the factors. This 209 identified ten countries that had significant presence and were subsequently used to 210 plot another OHLC chart ( Figure 5 ) . Only tCD34 has sufficient data--points within the 211 dataset to plot with significance. 212
For each country, the number of centres contributing towards the result has been 213 annotated. It is difficult discern differences between countries without much greater 214 resolution, because each of these centres will probably operate under different 215 practises / equipment / staff, and target different indications and patients. However, 216
there is sufficient evidence that biological variation is a global concern. 217
Variation as a Function of Study Size 218
As the number of donor / patients involved in a study increased, the amount of 219 variation also increased. 220 Figure 6 is a stratified scatter diagram of the range of tCD34 / kg / study against the 221 number of patients / donors in the study. SROCs were carried out for each 222 subsection and have been included in this diagram ( a -f ). These statistically 223 significant correlations demonstrate that as the size of the study increases ( and 224 therefore the number of donors and products involved ) the total variation per study 225 increases. From a variation perspective this not only indicates that the current lab--226 based production methods find it increasingly difficult to process large volumes of 227 product in a consistent manner, but will most probably be unsuitable for large scale 228 production of a future therapeutic. 229
Meta--Analysis Limitations 230
Due to the disparate and aggregated nature of how public data is reported and 231 subsequently collected in this study, a number of limitations must be considered 232 when regarding these results. 233
• Outliers. In biological manufacturing, 'outliers' can be representative of the 234 heterogeneity of an individual's biological state ( and/or their personalised 235 medicine ), so cannot be disregarded. 236
• Sampling Variation. There may be an element of author bias which may have 237 resulted in data--containing studies being overlooked, but given the overallspread of the data the authors do not anticipate any significant shift in statistical 239 behaviour. 240
• Duplicate Data. Due to conglomerate groups, such as the European Bone 241
Marrow Transplant Group ( EBMT ), there is a risk of overlapping data. This is a 242 problem that using dedicated raw data will not encounter. 243
• Patient versus Donor Weight. cCD34 and tCD34 were reported as cells per kg of 244 patient bodyweight, ideally they would have to be first normalised to donor 245 bodyweight -( in autologous therapy, this is not an issue because the patient is 246 also the donor ) -for allogeneic therapy this would be an instance of adding 247 distance from the true value. 248
• Paediatric Analysis. This meta--analysis contained a total of 18 paediatric donor 249 based studies and therefore a separate analysis regarding children has not been 250 made, or a comparison between adult and paediatric cCD34 and tCD34. However 251 importantly, autoimmune disease, inherited metabolic disorders and gene 252 therapy are all prime targets for paediatric therapy 6 and an understanding of 253 paediatric variation would be beneficial. 254
• Mobilisation / Conditioning Regime. These are difficult to quantify because they 255 vary on a case--by--case basis, in terms of dosage, regime, drugs, clinician 7 and a 256 combination of these. Additionally, details were not uniformly reported. These 257 regimes are crucial factors 8 in the content and quality of the starting material for 258 HSCT and proper characterisation and stratification is vital to a better 259
understanding. 260
• Apheresis / Aspiration Processes. Details regarding the instrumentation used for 261 apheresis, flow rates, number of procedures or extractions were rarely reported. 262
Furthermore it is not clear from the literature whether cCD34 is taken from the 263 total collected cell count, or from a particular stage -or how many extractions 264 were used. It is common clinical practise to pool individual products but it is 265 unclear which ( if any ) of the reported metrics are pooled products. The number 266 of collections is also a factor in addition to patient health 9 . 267
• Cryopreservation and Transport. It is accepted that cryopreservation causes 268 losses in TNC, viability and CD34+ cell numbers 10 but it is unclear as to whether 269 this loss, is a contributing factor towards variation. 270
• Multiple Centres. There are a number of centres with multiple observations 271 within the dataset, but not sufficient numbers to make meaningful statistical 272 observations regarding the variation between and within centres. The use of raw 273 data from clinical centres would be needed to allow this comparison. 274
• Raw Materials versus Starting Materials. Another variable are additional 275 chemicals added to the product. The UK MHRA has defined these as 'raw 276 materials', whilst the biological component is the 'starting material' and it is 277 important to understand the effect both have on each other and the process. 278
• Indication. Patient disease state was too generalised to stratify from the dataset.
Conclusion and Summary 280
This meta--analysis of publically available data has been developed to provide a broad--scope 281 demonstration of the challenge that biological input variation imposes on the potential for 282 controlling large scale bio--manufacture and will impose when manufacturing Advanced 283 Therapy Medicinal Products. The primary output from this analysis are results that 284 represent the extent of biological variation in both collected and transplanted material for a 285 clinical sub--population. 286
This meta--analysis has determined that; 287
• The current variation encountered under the practice of medicine for 288 haematopoietic stem cell therapy can be up to six orders of magnitude of the 289 median dose. This level of variation would be unmanageable from a bio--290 manufacturing perspective. 291
• Comparing the ranges of collected and transplanted CD34+ cells over time, there is 292 little evidence to suggest an improvement in the community's ability to control the 293 variation in HSCT over the last three decades. 294
• There is a weak negative correlation between collected CD34+ cells and study start 295 year, which may represent improvement in apheresis technology, but the range of 296 transplanted CD34+ cells remains inconsistent over the thirty years. This has 297 potential implications for comparable efficacy, patient outcome, and mode of action. 298
It is clear that to make the next decisions on an appropriate bio--manufacturing strategy, a 299 stratifiable data source with greater resolution will be required; such as patient databases 300 and centre--specific clinical records. Without this raw data, quantification of sources and 301 extent of variation contributed by each variable will remain informed speculation. 302
Consequently the next step in this research is the acquisition and analysis of high quality 303 datasets from clinical petitioned national health sources, where the data represents 304 individual cases, not summaries. This will allow stratification of the contributions of 305 variables such as donor age or weight, process parameters and indication and an increased 306 rigour and quality in the reported results. This will also allow access to absolute numbers of 307 cells per collection / product. Additionally, using datasets from specific centres will allownormalisation of the variation with respect to centre specific factors, such as geographical, 309 surgical, clinical and operator variation, because these should remain constant within a 310 
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